Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curtis Triplitt

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
The American Journal of Managed Care|September 3, 2010
Improving treatment success rates for type 2 diabetes: recommendations for a changing environmentCurtis Triplitt
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists|August 24, 2010
Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough?Curtis Triplitt
Clinical Medicine Insights. Endocrinology and Diabetes|November 3, 2015
Canagliflozin Treatment in Patients with Type 2 Diabetes MellitusCurtis Triplitt, Susan Cornell
Journal of the American Pharmacists Association : Japha|March 15, 2006
Exenatide: from the Gila monster to the pharmacyCurtis Triplitt, Elaine Chiquette
The Diabetes Educator|October 10, 2015
GLP-1 Receptor Agonists: Practical Considerations for Clinical PracticeCurtis Triplitt, Carolina Solis-Herrera
Expert Review of Endocrinology & Metabolism|February 16, 2019
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitusCurtis Triplitt, Ralph A DeFronzo
Diabetes, Obesity & Metabolism|October 27, 2023
Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetesCarolina Solis-Herrera, Curtis Triplitt
Journal of Managed Care Pharmacy : JMCP|September 20, 2006
What are incretins, and how will they influence the management of type 2 diabetes?Lawrence Blonde, Julio Rosenstock, Curtis Triplitt
Pharmacotherapy|March 1, 2006
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitusCurtis Triplitt, Alison Wright, Elaine Chiquette
Advances in Therapy|March 23, 2019
Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the PharmacistDhiren Patel, Curtis Triplitt, Jennifer Trujillo
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
The American Journal of Managed Care|September 3, 2010
Improving treatment success rates for type 2 diabetes: recommendations for a changing environmentCurtis Triplitt
The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists|August 24, 2010
Cardiac risk factors and hypoglycemia in an elderly patient: how good is good enough?Curtis Triplitt
Clinical Medicine Insights. Endocrinology and Diabetes|November 3, 2015
Canagliflozin Treatment in Patients with Type 2 Diabetes MellitusCurtis Triplitt, Susan Cornell
Journal of the American Pharmacists Association : Japha|March 15, 2006
Exenatide: from the Gila monster to the pharmacyCurtis Triplitt, Elaine Chiquette
The Diabetes Educator|October 10, 2015
GLP-1 Receptor Agonists: Practical Considerations for Clinical PracticeCurtis Triplitt, Carolina Solis-Herrera
Expert Review of Endocrinology & Metabolism|February 16, 2019
Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitusCurtis Triplitt, Ralph A DeFronzo
Diabetes, Obesity & Metabolism|October 27, 2023
Non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetesCarolina Solis-Herrera, Curtis Triplitt
Journal of Managed Care Pharmacy : JMCP|September 20, 2006
What are incretins, and how will they influence the management of type 2 diabetes?Lawrence Blonde, Julio Rosenstock, Curtis Triplitt
Pharmacotherapy|March 1, 2006
Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitusCurtis Triplitt, Alison Wright, Elaine Chiquette
Advances in Therapy|March 23, 2019
Appropriate Titration of Basal Insulin in Type 2 Diabetes and the Potential Role of the PharmacistDhiren Patel, Curtis Triplitt, Jennifer Trujillo
Pageof 6